Table 3.

Voting results

Scenario	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree	% Agree or Strongly Agree
1: Delay initiation of screening	24	…	…	…	…	100
2: Delay annual screening	23	1	…	…	…	100
3: Delay surveillance of solid nodule < 8 mm	18	5	1	…	…	96
4: Delay surveillance of Lung-RADS category 3 nodule	17	5	1	…	…	96
5: Delay surveillance of ground-glass nodule	19	5	…	…	…	100
6: Delay surveillance of part-solid 6-8 mm nodule	15	8	1	…	…	96
7: Delay surveillance of solid nodule ≥ 8 mm, pCA < 10%	8	13	2	1	…	88
8: Monitor solid nodule ≥ 8 mm, pCA 10%-25%, in 3-6 mo	6	12	1	5	…	75
9: Monitor part-solid nodule ≥ 8 mm in 3-6 mo	9	11	2	2	…	83
10: Evaluate solid nodule ≥ 8 mm, pCA 65%-85%	12	7	2	2	1	79
11: Avoid further diagnostic testing of solid nodule ≥ 8 mm, pCA > 85%	11	9	2	1	…	87
12: Consider delay in treatment of stage I NSCLC	15	9	…	…	…	100

NSCLC = non–small-cell lung cancer; pCA = probability of malignancy. See Table 1 legend for expansion of other abbreviation.